Jazz Pharmaceuticals plc (JAZZ) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Jazz Pharmaceuticals reported revenue of $4.27B, up 4.9% from $4.07B the year before. Net income was -$356.1M (a -8.3% net margin), or -$5.84 per diluted share. Gross margin was -10.1% and operating margin was -10.1%. Operating activities generated $1.36B of cash, leaving $1.30B of free cash flow. At fiscal year end, Jazz Pharmaceuticals held $11.66B in total assets against $7.34B in total liabilities, including $1.39B of cash and equivalents.
Open the full interactive Jazz Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Jazz Pharmaceuticals Key Stats
| Share Price | $210.39 |
|---|---|
| Market Cap | $14.60B |
| Revenue YoY Growth | +4.9% |
| 52-Week Range | $131.16 – $261.62 |
| Shares Outstanding | 63.2 million (basic, 2026 Q2) |
Jazz Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.36B | $3.09B | $3.66B | $3.83B | $4.07B | $4.27B |
| Cost of Goods Sold | $1.99B | $2.92B | $3.72B | $3.26B | $3.35B | $4.70B |
| Gross Profit | $378.1M | $170.3M | -$65.5M | $578.6M | $716.6M | -$430.2M |
| Operating Income | $378.1M | $170.3M | -$65.5M | $578.6M | $716.6M | -$430.2M |
| Pre-Tax Income | $275.1M | -$112.8M | -$372.8M | $297.9M | $470.4M | -$627.9M |
| Income Tax | $33.5M | $216.1M | -$158.6M | -$119.9M | -$91.4M | -$272.4M |
| Net Income | $238.6M | -$329.7M | -$224.1M | $414.8M | $560.1M | -$356.1M |
| Diluted EPS | $4.22 | -$5.52 | -$3.58 | $6.10 | $8.65 | -$5.84 |
Jazz Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.13B | $1.20B | $1.07B | $1.21B |
| Net Income | $251.4M | $203.5M | $293.1M | $192.8M |
| Diluted EPS | $4.08 | $3.34 | $4.43 | $2.78 |
Jazz Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.06B | $591.4M | $881.5M | $1.51B | $2.41B | $1.39B |
| Current Assets | $2.84B | $2.61B | $2.61B | $3.44B | $4.63B | $4.17B |
| Total Assets | $6.54B | $12.30B | $10.84B | $11.39B | $12.01B | $11.66B |
| Current Liabilities | $653.7M | $809.3M | $933.2M | $1.54B | $1.04B | $2.24B |
| Total Long-Term Debt | $2.09B | $6.05B | $5.72B | $5.71B | $6.11B | $5.36B |
| Total Liabilities | $2.88B | $8.33B | $7.75B | $7.66B | $7.92B | $7.34B |
| Shareholders' Equity | $3.66B | $3.97B | $3.09B | $3.74B | $4.09B | $4.32B |
Jazz Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $899.6M | $778.5M | $1.27B | $1.09B | $1.40B | $1.36B |
| Cash From Investing | -$1.01B | -$5.21B | -$446.2M | -$163.1M | -$508.2M | -$1.51B |
| Cash From Financing | $528.1M | $3.97B | -$529.5M | -$305.3M | $20.5M | -$873.4M |
| Free Cash Flow | $884.6M | $750.9M | $1.24B | $1.07B | $1.36B | $1.30B |
Figures from Jazz Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Jazz Pharmaceuticals financials page for every line item.
Jazz Pharmaceuticals Company Profile
| Ticker | JAZZ |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Dublin |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001232524 |
Frequently Asked Questions
What was Jazz Pharmaceuticals' revenue in fiscal 2025?
Jazz Pharmaceuticals (JAZZ) reported revenue of $4.27B for fiscal 2025.
What is Jazz Pharmaceuticals' annual revenue history?
Jazz Pharmaceuticals' annual revenue by fiscal year: 2020: $2.36B; 2021: $3.09B; 2022: $3.66B; 2023: $3.83B; 2024: $4.07B; 2025: $4.27B.
What was Jazz Pharmaceuticals' net income in fiscal 2025?
Jazz Pharmaceuticals reported net income of -$356.1M for fiscal 2025.
What was Jazz Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Jazz Pharmaceuticals' diluted EPS was -$5.84 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Jazz Pharmaceuticals generate in fiscal 2025?
Jazz Pharmaceuticals generated $1.30B of free cash flow in fiscal 2025.
What was Jazz Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Jazz Pharmaceuticals reported revenue of $1.21B.
How much debt does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals reported $5.36B of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Jazz Pharmaceuticals are outstanding?
Jazz Pharmaceuticals reported a weighted average of 63.2 million basic shares outstanding in 2026 Q2.
What is Jazz Pharmaceuticals' market cap?
Based on its latest closing price, Jazz Pharmaceuticals (JAZZ) has a market capitalization of about $14.60B.
When does Jazz Pharmaceuticals' fiscal year end?
Jazz Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals lists its business address in Dublin in its SEC filings.